{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dutta D"],"funding":["Department of Biotechnology, Govt. of India"],"pagination":["81"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11334571"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(1)"],"pubmed_abstract":["<h4>Background</h4>Betulinic acid (BA) has been well investigated for its antiproliferative and mitochondrial pathway-mediated apoptosis-inducing effects on various cancers. However, its poor solubility and off-target activity have limited its utility in clinical trials. Additionally, the immune modulatory role of betulinic acid analogue in the tumor microenvironment (TME) is largely unknown. Here, we designed a potential nanotherapy for colorectal cancer (CRC) with a lead betulinic acid analogue, named as 2c, carrying a 1,2,3-triazole-moiety attached to BA through a linker, found more effective than BA for inhibiting CRC cell lines, and was chosen here for this investigation. Epithelial cell adhesion molecule (EpCAM) is highly overexpressed on the CRC cell membrane. A single-stranded shor"],"journal":["Journal of biomedical science"],"pubmed_title":["EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment."],"pmcid":["PMC11334571"],"funding_grant_id":["DBT/RA/16/05/2016"],"pubmed_authors":["Banerjee S","Park JH","Al Hoque A","Mukherjee B","Boro P","Quadir M","Sepay N","Dutta D","Kaipparettu BA","Laha S","Chowdhury C","Paul B","Choudhury A"],"additional_accession":[]},"is_claimable":false,"name":"EpCAM-targeted betulinic acid analogue nanotherapy improves therapeutic efficacy and induces anti-tumorigenic immune response in colorectal cancer tumor microenvironment.","description":"<h4>Background</h4>Betulinic acid (BA) has been well investigated for its antiproliferative and mitochondrial pathway-mediated apoptosis-inducing effects on various cancers. However, its poor solubility and off-target activity have limited its utility in clinical trials. Additionally, the immune modulatory role of betulinic acid analogue in the tumor microenvironment (TME) is largely unknown. Here, we designed a potential nanotherapy for colorectal cancer (CRC) with a lead betulinic acid analogue, named as 2c, carrying a 1,2,3-triazole-moiety attached to BA through a linker, found more effective than BA for inhibiting CRC cell lines, and was chosen here for this investigation. Epithelial cell adhesion molecule (EpCAM) is highly overexpressed on the CRC cell membrane. A single-stranded shor","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-02T04:47:30.826Z","creation":"2025-04-05T12:29:26.184Z"},"accession":"S-EPMC11334571","cross_references":{"pubmed":["39164686"],"doi":["10.1186/s12929-024-01069-8"]}}